Quince Therapeutics, Inc.(QNCX)Earnings, Financials & Key Ratios
QNCX•NASDAQ
$1.30
$7M mkt cap·Price updated May 7, 2026
AboutQuince Therapeutics, Inc., a biopharmaceutical company, focuses on advancing precision therapeutics for debilitating and rare diseases. The company has discovered a broad bone-targeting drug platform to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease. Its lead compound is NOV004, an anabolic peptide engineered to precisely target and concentrate at the bone fracture site The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.Show more
- Revenue$0
- EBITDA-$50M+11.9%
- Net Income-$84M-47.8%
- EPS (Diluted)-16.80-28.2%
- ROIC-485.58%-560.6%
QNCX Key Insights
Quince Therapeutics, Inc. (QNCX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗Weak Piotroski F-Score: 1/9
- ✗Weak momentum: RS Rating 4 (bottom 4%)
- ✗Low quality earnings: Net income not backed by cash flow
- ✗Shares diluted 15.8% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
QNCX Price & Volume
Quince Therapeutics, Inc. (QNCX) stock price & volume — 10-year historical chart
Loading chart...
QNCX Growth Metrics
Quince Therapeutics, Inc. (QNCX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-47.78%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-28.24%
Return on Capital
10 Years-60.25%
5 Years-48.01%
3 Years-43.59%
Last Year-64.04%
QNCX Peer Comparison
Quince Therapeutics, Inc. (QNCX) competitors in Commercial Rare Disease Biopharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 RARE | 2.57B | 26.13 | -4.48 | 20.13% | -91.03% | -6.08% | ||
 FOLD | 4.55B | 14.49 | -164.85 | 20.05% | -4.27% | -12.02% | 1.76 | |
 ACAD | 3.86B | 22.57 | 9.85 | 11.87% | 34.3% | 35.65% | 0.04 | |
 PTCT | 5.35B | 64.49 | 8.29 | 114.51% | -22.58% | |||
 KRYS | 8.75B | 296.70 | 43.38 | 33.94% | 53.92% | 19.25% | 0.01 | |
 RCKT | 397.53M | 3.67 | -1.83 | -80.49% | 0.09 | |||
 SRPT | 2.18B | 20.80 | -2.92 | 15.58% | 2.98% | 4.89% | 0.91 | |
 BMRN | 10.41B | 54.12 | 30.07 | 12.87% | 8.29% | 4.41% | 0.11 |
Compare QNCX vs Peers
Quince Therapeutics, Inc. (QNCX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
QNCX Income Statement
Quince Therapeutics, Inc. (QNCX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 45K | 51K | 0 | 0 | 0 | 0 | 0 | 0 | 142K |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - |
| Gross Profit | -45K▲ 0% | -51K▼ 13.3% | 0▲ 100.0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | -142K▲ 0% |
| Gross Margin % | - | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | -13.33% | 100% | - | - | - | - | - | - |
| Operating Expenses | 10.37M | 12.12M | 39.17M | 78.89M | 90.32M | 52.02M | 34.62M | 57.28M | 50.29M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 1.27M | 2.03M | 8.95M | 17.59M | 29.52M | 26.01M | 17.7M | 17.58M | 15.05M |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - |
| Research & Development | 9.1M | 10.09M | 30.21M | 61.31M | 60.8M | 25.18M | 9.45M | 18.59M | 35.38M |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 825K | 7.48M | 21.11M | -142K |
| Operating Income | -10.37M▲ 0% | -12.12M▼ 16.9% | -39.17M▼ 223.2% | -78.89M▼ 101.4% | -90.32M▼ 14.5% | -52.02M▲ 42.4% | -34.62M▲ 33.4% | -57.28M▼ 65.5% | -50.43M▲ 12.0% |
| Operating Margin % | - | - | - | - | - | - | - | - | - |
| Operating Income Growth % | - | -16.87% | -223.19% | -101.42% | -14.48% | 42.41% | 33.44% | -65.47% | 11.97% |
| EBITDA | -10.32M | -12.07M | -38.98M | -78.56M | -89.97M | -51.81M | -34.3M | -57.1M | -50.29M |
| EBITDA Margin % | - | - | - | - | - | - | - | - | - |
| EBITDA Growth % | - | -16.88% | -223% | -101.54% | -14.53% | 42.42% | 33.8% | -66.48% | 11.93% |
| D&A (Non-Cash Add-back) | 45K | 51K | 188K | 332K | 344K | 204K | 322K | 186K | 142K |
| EBIT | -10.37M | -11.52M | -39.17M | -78.89M | -90.32M | -51.19M | -27.14M | -36.17M | -50.43M |
| Net Interest Income | 0 | -151K | 2.19M | 2.04M | 620K | 500K | 3.48M | 2.93M | 1.24M |
| Interest Income | 0 | 806K | 2.19M | 2.04M | 620K | 1.07M | 3.48M | 2.93M | 1.24M |
| Interest Expense | 1.64M | 957K | 0 | 0 | 0 | 568K | 0 | 0 | 0 |
| Other Income/Expense | -1.86M | -357K | 2.19M | 2.04M | 373K | 71K | 3.04M | 544K | -30.34M |
| Pretax Income | -12.23M▲ 0% | -12.48M▼ 2.0% | -36.98M▼ 196.4% | -76.85M▼ 107.8% | -89.94M▼ 17.0% | -51.94M▲ 42.2% | -31.58M▲ 39.2% | -56.74M▼ 79.7% | -80.77M▼ 42.3% |
| Pretax Margin % | - | - | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | -284K | -197K | 87K | 3.21M |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0.55% | 0.62% | -0.15% | -3.98% |
| Net Income | -12.23M▲ 0% | -12.48M▼ 2.0% | -36.98M▼ 196.4% | -76.85M▼ 107.8% | -89.94M▼ 17.0% | -51.66M▲ 42.6% | -31.39M▲ 39.2% | -56.83M▼ 81.1% | -83.98M▼ 47.8% |
| Net Margin % | - | - | - | - | - | - | - | - | - |
| Net Income Growth % | - | -1.97% | -196.41% | -107.81% | -17.04% | 42.56% | 39.25% | -81.07% | -47.78% |
| Net Income (Continuing) | -12.23M | -12.48M | -36.98M | -76.85M | -89.94M | -51.66M | -31.39M | -56.83M | -83.98M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -5.70▲ 0% | -5.80▼ 1.8% | -19.30▼ 232.8% | -26.30▼ 36.3% | -30.30▼ 15.2% | -15.40▲ 49.2% | -8.40▲ 45.5% | -13.10▼ 56.0% | -16.80▼ 28.2% |
| EPS Growth % | - | -1.75% | -232.76% | -36.27% | -15.21% | 49.17% | 45.45% | -55.95% | -28.24% |
| EPS (Basic) | -5.70 | -5.80 | -19.30 | -26.30 | -30.30 | -15.40 | -8.40 | -13.10 | -16.80 |
| Diluted Shares Outstanding | 2.16M | 2.16M | 1.9M | 2.92M | 2.97M | 3.35M | 3.72M | 4.33M | 5.01M |
| Basic Shares Outstanding | 2.16M | 2.16M | 1.9M | 2.92M | 2.97M | 3.35M | 3.72M | 4.33M | 5.01M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
QNCX Balance Sheet
Quince Therapeutics, Inc. (QNCX) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 7.54M | 72.58M | 106.06M | 137.86M | 111.67M | 93.75M | 77.44M | 44.04M | 22.9M |
| Cash & Short-Term Investments | 7.34M | 71.72M | 99.86M | 133.82M | 106.8M | 90.18M | 75.06M | 40.78M | 17.75M |
| Cash Only | 7.34M | 24.87M | 51.21M | 66.84M | 69.72M | 44.58M | 20.75M | 6.21M | 5.81M |
| Short-Term Investments | 0 | 46.84M | 48.65M | 66.98M | 37.08M | 45.6M | 54.31M | 34.57M | 11.94M |
| Accounts Receivable | 0 | 0 | 0 | 0 | 1.13M | 0 | 993K | 882K | 3.62M |
| Days Sales Outstanding | - | - | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 143K | 821K | 688K | 694K | 367K | 2.37M | 81K | 84K | 1.52M |
| Total Non-Current Assets | 181K | 293K | 18.31M | 51.6M | 21.55M | 10.16M | 102.76M | 70.44M | 70.63M |
| Property, Plant & Equipment | 122K | 283K | 1.33M | 1.1M | 1.43M | 684K | 619K | 813K | 1.05M |
| Fixed Asset Turnover | - | - | - | - | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 17.63M | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 5.9M | 63.67M | 60.05M | 67.82M |
| Long-Term Investments | 0 | 0 | 16.76M | 50.46M | 19.93M | 3.58M | 78K | 78K | 78K |
| Other Non-Current Assets | 59K | 10K | 217K | 39K | 194K | 3.58M | 8.47M | 9.51M | 1.68M |
| Total Assets | 7.72M▲ 0% | 72.88M▲ 844.3% | 124.37M▲ 70.7% | 189.47M▲ 52.3% | 133.23M▼ 29.7% | 103.91M▼ 22.0% | 180.2M▲ 73.4% | 114.48M▼ 36.5% | 93.52M▼ 18.3% |
| Asset Turnover | - | - | - | - | - | - | - | - | - |
| Asset Growth % | - | 844.26% | 70.66% | 52.34% | -29.68% | -22.01% | 73.42% | -36.47% | -18.3% |
| Total Current Liabilities | 1.76M | 1.46M | 8.89M | 17M | 14.22M | 3.07M | 9.57M | 7.28M | 43.23M |
| Accounts Payable | 517K | 495K | 3.08M | 3.56M | 4.91M | 570K | 2.03M | 2.9M | 2.22M |
| Days Payables Outstanding | 4.19K | 3.54K | - | - | - | - | - | - | 5.71K |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 64K | 0 | 18.03M |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 0 | 10.79M | 180K | 916K | 5.13M | 308K | 22.98M |
| Current Ratio | 4.28x | 49.82x | 11.93x | 8.11x | 7.85x | 30.55x | 8.09x | 6.05x | 0.53x |
| Quick Ratio | 4.28x | 49.82x | 11.93x | 8.11x | 7.85x | 30.55x | 8.09x | 6.05x | 0.53x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 26.23M | 495K | 3.08M | 208K | 420K | 248K | 85.55M | 77.05M | 86.01M |
| Long-Term Debt | 7.17M | 0 | 0 | 0 | 0 | 0 | 13.43M | 14.32M | 330K |
| Capital Lease Obligations | 0 | 0 | 0 | 208K | 420K | 0 | 321K | 394K | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 248K | 17.61M | 4.96M | 0 |
| Other Non-Current Liabilities | 19.06M | 0 | 0 | 0 | 0 | 0 | 54.19M | 57.38M | 85.68M |
| Total Liabilities | 28M | 1.46M | 8.89M | 17.2M | 14.64M | 3.32M | 95.12M | 84.33M | 129.24M |
| Total Debt | 7.17M | 0 | 0 | 446K | 1.16M | 453K | 13.81M | 14.81M | 18.36M |
| Net Debt | -172K | -24.87M | -51.21M | -66.39M | -68.56M | -44.13M | -6.94M | 8.6M | 12.55M |
| Debt / Equity | - | - | - | 0.00x | 0.01x | 0.00x | 0.16x | 0.49x | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Interest Coverage | -6.31x | -12.04x | - | - | - | -90.12x | - | - | - |
| Total Equity | -20.28M▲ 0% | 71.42M▲ 452.2% | 115.48M▲ 61.7% | 172.26M▲ 49.2% | 118.59M▼ 31.2% | 100.59M▼ 15.2% | 85.08M▼ 15.4% | 30.15M▼ 64.6% | -35.71M▼ 218.5% |
| Equity Growth % | - | 452.17% | 61.69% | 49.17% | -31.16% | -15.17% | -15.42% | -64.57% | -218.47% |
| Book Value per Share | -9.41 | 33.14 | 60.68 | 59.04 | 39.90 | 30.03 | 22.85 | 6.97 | -7.13 |
| Total Shareholders' Equity | -20.28M | 71.42M | 115.48M | 172.26M | 118.59M | 100.59M | 85.08M | 30.15M | -35.71M |
| Common Stock | 3K | 22K | 27K | 29K | 30K | 36K | 43K | 44K | 55K |
| Retained Earnings | -20.35M | -32.83M | -69.81M | -146.65M | -236.6M | -288.26M | -319.64M | -376.47M | -460.45M |
| Treasury Stock | 0 | -220K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -17.18M | -49K | 60K | 313K | -79K | -289K | 3.05M | -35K | 5.75M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
QNCX Cash Flow Statement
Quince Therapeutics, Inc. (QNCX) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -9.83M | -11.7M | -33.28M | -50.82M | -62.93M | -44.04M | -18.29M | -31.9M | -41.42M |
| Operating CF Margin % | - | - | - | - | - | - | - | - | - |
| Operating CF Growth % | - | -19.01% | -184.54% | -52.71% | -23.84% | 30.02% | 58.46% | -74.41% | -29.84% |
| Net Income | -12.23M | -12.48M | -36.98M | -76.85M | -89.94M | -51.66M | -31.39M | -56.83M | -83.98M |
| Depreciation & Amortization | 45K | 51K | 188K | 332K | 344K | 204K | 322K | 186K | 142K |
| Stock-Based Compensation | 38K | 155K | 2.06M | 14.47M | 29.85M | 16.62M | 5.22M | 4.75M | 5.11M |
| Deferred Taxes | 222K | -145K | -812K | 635K | 878K | -284K | -248K | 0 | -4.96M |
| Other Non-Cash Items | 1.64M | 1.11M | 367K | 367K | 199K | 913K | 5.82M | 20.48M | 29.43M |
| Working Capital Changes | 460K | -390K | 1.9M | 10.23M | -4.26M | -9.83M | 1.98M | -484K | 12.84M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 223K | -23K | 2.58M | 480K | 1.36M | -5.94M | -288K | 927K | -940K |
| Cash from Investing | -77K | -46.75M | -17.75M | -52.43M | 58.95M | 18M | -5.76M | 21.91M | 23.23M |
| Capital Expenditures | -77K | -212K | -55K | -52K | -180K | -133K | -160K | -257K | -352K |
| CapEx % of Revenue | - | - | - | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | -812K | 52.43M | -58.95M | 10.59M | -2.12M | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | -46.54M | 812K | -52.43M | 58.95M | 70K | -910K | 2.35M | 1.01M |
| Cash from Financing | 7.75M | 75.93M | 77.37M | 118.88M | 6.81M | 707K | 143K | -4.78M | 17.91M |
| Debt Issued (Net) | 7.75M | 250K | -559K | -34K | 0 | -49K | -6K | 0 | 0 |
| Equity Issued (Net) | 0 | 75.69M | 77.83M | 117.63M | 6.81M | 608K | 149K | 225K | 17.91M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | -10K | 98K | 1.28M | 0 | 148K | 0 | -5M | 0 |
| Net Change in Cash | -2.15M▲ 0% | 17.48M▲ 911.5% | 26.34M▲ 50.7% | 15.63M▼ 40.7% | 2.88M▼ 81.6% | -25.14M▼ 972.2% | -23.83M▲ 5.2% | -14.54M▲ 39.0% | -403K▲ 97.2% |
| Free Cash Flow | -9.9M▲ 0% | -11.91M▼ 20.2% | -33.33M▼ 179.9% | -50.87M▼ 52.6% | -63.11M▼ 24.1% | -44.17M▲ 30.0% | -18.45M▲ 58.2% | -32.16M▼ 74.3% | -41.78M▼ 29.9% |
| FCF Margin % | - | - | - | - | - | - | - | - | - |
| FCF Growth % | - | -20.22% | -179.94% | -52.62% | -24.07% | 30.01% | 58.23% | -74.3% | -29.9% |
| FCF per Share | -4.60 | -5.52 | -17.51 | -17.44 | -21.24 | -13.19 | -4.96 | -7.43 | -8.34 |
| FCF Conversion (FCF/Net Income) | 0.80x | 0.94x | 0.90x | 0.66x | 0.70x | 0.85x | 0.58x | 0.56x | 0.49x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 1K | 1K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
QNCX Key Ratios
Quince Therapeutics, Inc. (QNCX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | -48.79% | -39.57% | -53.42% | -61.85% | -47.14% | -33.81% | -98.63% | - |
| Return on Invested Capital (ROIC) | - | -69.66% | -53.02% | -69.56% | -86.91% | -73.27% | -38.58% | -73.51% | -485.58% |
| Debt / Equity | - | - | - | 0.00x | 0.01x | 0.00x | 0.16x | 0.49x | - |
| Interest Coverage | -6.31x | -12.04x | - | - | - | -90.12x | - | - | - |
| FCF Conversion | 0.80x | 0.94x | 0.90x | 0.66x | 0.70x | 0.85x | 0.58x | 0.56x | 0.49x |
QNCX Frequently Asked Questions
Quince Therapeutics, Inc. (QNCX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Quince Therapeutics, Inc. (QNCX) grew revenue by 0.0% over the past year. Growth has been modest.
Quince Therapeutics, Inc. (QNCX) reported a net loss of $84.0M for fiscal year 2025.
Dividend & Returns
Quince Therapeutics, Inc. (QNCX) had negative free cash flow of $48.1M in fiscal year 2025, likely due to heavy capital investments.
Explore More QNCX
Quince Therapeutics, Inc. (QNCX) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates